DEFINITE HEDERITARY FAMILIAL HYPERCHOLESTEROLEMIA IN YAKYTIA

Cardiovascular diseases occupy a leading position in the structure of mortality in most countries of the world, including Russia. The World Health Organization predicts further increases in cardiovascular morbidity and mortality in both developed and developing countries due to population aging and lifestyle patterns. Among the causes of cardiovascular mortality, IHD ranks first, followed by cerebrovascular disease, the main cause of the occurrence and development of which is atherosclerosis of the arteries, caused by a violation of lipid metabolism. The article discusses the role of the genetic factor in the formation of familial hypercholesterolemia and presents the first clinical cases with the results of molecular genetic confirmation of the low-density lipoprotein receptor gene mutation in patients of the Lipid Cabinet, Republic’s Clinical Hospital No. 3 with a diagnosis of “Definite” familial hypercholesterolemia. Despite the unconditional need for early detection of familial hypercholesterolemia for the primary prevention of atherosclerotic cardiovascular diseases, it should be noted that patients have low adherence to lipid-lowering therapy and low interest of the index patient in conducting cascade screening. Comparison of genetic differences in FH in the Yakut population between different ethnic groups requires further research.

1. Karpov Yu.A. Consensus statement of the Russian national atherosclerosis society (rnas) familial hypercholesterolemia in Russia: outstanding issues in diagnosis and management / Yu.A. Karpov, V.V. Kukharchuk, S.A. Boytsov [et all.] // Ateroskleroz i dislipidemii. – 2015. – 2(19):5-16 (In Russ.)

2. Meshkov A.N. Cross-sectional study to estimate the prevalence of familial hypercholesterolemia in selected regions of the Russian Federation: relevance, design of the study and initial characteristics of the participants / A.N. Meshkov, A.I. Ershova, S.A. Shalnova [et all.] // Rational Pharmacotherapy in Cardiology – 2020. – 16(1):24-32. (In Russ.)] DOI 10.20996/1819-6446-2020-02-17.

3. Yezhov M.V. Register Of Patients With Familial Hypercholesterolemia And Patients Of Very High Cardiovascular Risk With Lipid-Lowering Therapy Underperformance (Renessans) / M.V. Yezhov, S.A. Bliznyuk, N.A. Tmoyan [et all.] // Russian Journal of Cardiology – 2019. – 24 (5):7–13. (In Russ.) DOI 10.15829/15604071-2019-5-7-13

4. Rozhkova, T. A. Identification of patients with familial hypercholesterolemia in outpatient practice / T. A. Rozhkova, M. Yu. Zubareva // Eurasian Journal of Cardiology – 2016/ – No.3:74-75. (In Russ.)

5. Chubykina U.V. Cardiovascular events and effectiveness of hypolipidemic therapy in patients with familial hypercholesterolemia and patients of very high cardiovascular risk: 3-year follow-up of the renaissance registry / U.V. Chubykina, M.V. Ezhov, D.V. Duplyakov [et all.] // Kardiologicheskiy vestnik – 2020/- 3(15): 27-36. (In Russ.)] DOI 10.36396/MS.2020.16.3.004

6. Khripunova A.A. Epidemiology And Diagnostics Of Familial Hypercholesterolemia In The Russian Population/A.A. Khripunova, O.I. Boeva, A.R. Dzhanibekova [et all.] // Therapy – 2020. – 5(39):147-156. (In Russ.)] DOI 10.18565/therapy.2020.5.147-156.

7. Futema Marta. Genetic testing for familial hypercholesterolemia–past, present, and future/ Marta Futema, Alison Taylor-Beadling, Maggie Williams, Steve E. Humphries// Journal of lipid research – 2021.- 62-100139: https://www.jlr.org/article/S0022-2275(21)00121-8/fulltext

8. Nordestgaard B.G. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. /B.G. Nordestgaard, M.J. Chapman, S.E. Humphries (et al.)// Eur Heart J. – 2017.- 34(45): 3478-90a. DOI: 10.1093/eurheartj/eht273

9. Mach F. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. /F Mach , C Baigent, A.L. Catapano , K.C. Koskinas, M. Casula , L. Badimon , M.J. Chapman, G.G. DeBacker , V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund, //ESC Scientific Document Group. Eur Heart J. 2020; 41(1): 111–188. DOI:10.1093/eurheartj/ehz455. https://www.atherosclerosis-journal.com/article/S0021-9150(19)31459-5/fulltext

10. About the NHS Long-term Plan URL: https://www.longtermplan.nhs.uk/ (accessed: 30.07.2022).

11. Huang C.C. Genetic Diagnosis of Familial Hypercholesterolemia in Asia/ C.C. Huang, M.J. Charng MJ// Front Genet – 2020 Jul 24;11:833. doi: 10.3389/fgene.2020.00833. PMID: 32793292; PMCID: PMC7393677.